Authors
Latest:
Highlighting Advantages of Radiation in Lung CancerSilvia C. Formenti, MD, discusses the advantages of radiation therapy in patients with lung cancer compared to other modalities.
Latest:
The Use of Chemotherapy in Lung CancerSilvia Novello, MD, PhD, discusses the use of chemotherapy in lung cancer.
Latest:
Expanding on Data Surrounding Isatuximab Plus Pomalidomide/Dexamethasone in R/R MyelomaSimon J. Harrison, MD, gives key takeaways from his presentation on the ICARIA-MM study, which he recently presented at the 2019 International Myeloma Workshop.<br />
Latest:
Rule Discusses the Potential of Zanubrutinib in the Treatment of Mantle Cell LymphomaSimon Rule, MD, PhD, shares his thoughts on the FDA’s decision to grant zanubrutinib, a BTK inhibitor, priority review for the treatment of patients with mantle cell lymphoma. Should the drug be approved, it will be available for patients with MCL who have received at least 1 prior line of therapy.
Latest:
GVAX for Patients With Pancreatic CancerSmitha Krishnamurthi, MD, associate professor of medicine, Case Western Reserve University, describes GVAX for patients with metastatic pancreatic adenocarcinoma.
Latest:
Targeting B-Cell Lymphomas With T-Cell TherapiesSonali M. Smith, MD, discusses how T-cell–directed therapies work in the context of indolent B-cell lymphoma.
Latest:
Sonja Althammer Discusses Biomarkers for Durvalumab in Lung CancerSonja Althammer, PhD, Team Leader Bioinformatics at Definiens, discusses a study looking to define a subgroup of patients with non–small cell lung cancer who respond best to treatment with the PD-L1 inhibitor durvalumab.
Latest:
The Benefit of Radiotherapy/Antiandrogen Combination in Men With Locally Advanced Prostate CancerSophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.
Latest:
Exploring the Potential of CAR T-Cell Therapy in Head and Neck CancerSophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.
Latest:
Scheduling Tool Improves Infusion Center EfficiencyCoordinating appointments between the physician office suite and infusion center improved dramatically with the use of a scheduling optimization tool at the Cowell Family Cancer Center in Traverse City, Michigan. Specifically, the investigators observed a 6% reduction in median office-visit time and a 43% reduction in patient wait time in the infusion chair before infusion began.
Latest:
Can Rusfertide Eliminate Need For Phlebotomy in Polycythemia Vera Treatment?Srdan Verstovsek, MD, PhD, discusses the main reasons for his study on the use of rusfertide in patients with polycythemia vera.
Latest:
Discussing the Impact of the Momelotinib on Myelofibrosis ConditionsSrdan Verstovsek, MD, PhD, discusses the importance of the findings of the MOMENTUM trial, which assessed the use of momelotinib in managing anemia for patients with myelofibrosis.
Latest:
Overcoming Challenges in Treating Patients With Triple-Negative Breast CancerStacy L. Moulder, MD, discusses the challenges in drug development for triple-negative breast cancer, specifically in the neoadjuvant setting.
Latest:
Dr. Loeb Discusses the Controversy of Screening and Treatment in Prostate CancerStacy Loeb, MD, assistant professor, Urology and Population Health, NYU Langone Medical Center, discusses the controversy of screening and treatment in men with prostate cancer, as well as data from the National Prostate Cancer Register (NPCR) of Sweden.
Latest:
Twitter and UrologyStacy Loeb, MD, MSc, assistant professor, Department of Urology, Population Health, New York University, at the 2014 AUA Annual Meeting, discusses how urologists can use Twitter.
Latest:
FDA Approves Second-Line Axi-Cel for Adults With LBCLThe FDA has granted approval to axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy, according to an announcement from the FDA.
Latest:
Next Steps in Neoadjuvant Chemotherapy for Muscle-Invasive Bladder CancerStanley Yap, MD, assistant professor, urologic oncology, UC Davis Comprehensive Cancer Center, discusses needed improvements and next steps in neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Latest:
Sequester Forcing Chemo Treatments Into Hospitals Costing Taxpayers MoreThe federal sequester trims Medicare payments for cancer patients receiving chemotherapy in doctors’ offices in an effort to save the government money. Instead, it will end up costing more in the long run, according to the president of the American Society of Clinical Oncology.
Latest:
The Role of CD8 T Cells in MelanomaStefani Spranger, PhD, discusses how the presence or absence of CD8-positive T cells can affect treatment approaches for patients with melanoma.
Latest:
KIT Mutations Provide Accurate Prediction of Outcome in GIST DiagnosisPhysicians may be able to use KIT mutations to help predict the progression of gastrointestinal stromal tumors (GISTs), according to a new meta-analysis published in Nature Scientific Reports.
Latest:
CAR T Cell Data for Pediatric and Young Adult Patients With Relapsed/Refractory ALLStephan Grupp, MD, PhD, discusses updated findings from the phase II ELIANA trial of tisagenlecleucel (Kymriah), a chimeric antigen receptor T-cell therapy, in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high disease burden.
Latest:
Augmenting T Cell Immunity in Cold TumorsStephanie K. Dougan, MD, assistant professor, Dana-Farber Cancer Institute and Harvard Medical School, discusses the idea of augmenting T cell immunity in tumors that are poorly immunogenic, such as pancreatic cancer.
Latest:
Chronic Lymphocytic Leukemia: 2013 UpdateClinical study results presented at the 2013 American Society of Clinical Oncology Annual Meeting may offer new hope for patients with chronic lymphocytic leukemia.
Latest:
Real-World PSA Response Data Similar to Clinical Trials in Prostate CancerStephen J. Freedland, MD, discusses real-world data for enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer compared with data from the phase III PREVAIL study.
Latest:
Overview of the LAURA StudyPanelists give an overview of the LAURA trial, highlighting its objectives, methodologies, and key findings related to chronic spontaneous urticaria management.
Latest:
Dr. Stephen Nimer on MSI2 as a Requirement for Maintaining Activated MDS Stem CellsStephen Nimer, MD, leukemia and lymphoma treatment specialist, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses results of a study which examined Musashi2 as a requirement for maintaining activated myelodysplastic syndrome (MDS) cells.
